title: CMV retinitis in the era of HAART.
abstract: Since 1996, major advances in the treatment of AIDS have markedly changed the incidence and the prognosis of CMV retinitis. Highly active antiretroviral therapy (HAART) is a combination of nucleoside reverse transcriptase inhibitors and protease inhibitors. This new therapeutic strategy is highly efficient in reducing the HIV viral load and increasing CD(4)+ T-lymphocyte count. These biological effects are associated with an improvement of immune functions. Clinically, the completely quiescent CMV retinitis and the unusual prolonged relapse-free interval suggest a certain restoration of immune functions, making possible the discontinuation of maintenance therapy. For most authors, the decision to stop anti-CMV maintenance therapy is based on a CD4+ cell count >100 cells/microl with a low HIV viral load for at least four months. The improvement of CMV retinitis on HAART may also be associated with an intraocular inflammation called immune recovery vitritis. For some patients, this vitritis may be associated cystoid macular edema and an epiretinal membrane responsible for visual loss.
authors.affiliation: Department of Ophthalmology, Piti¿e-Salp¿etri¿ere Hospital, Paris, France.
authors.forename: N
authors.initials: N
authors.lastname: Cassoux
authors.forename: B
authors.initials: B
authors.lastname: Bodaghi
authors.forename: C
authors.initials: C
authors.lastname: Katlama
authors.forename: P
authors.initials: P
authors.lastname: LeHoang
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D019380:Anti-HIV Agents / Q000627:therapeutic use*; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D006801:Humans; D012173:Retinitis / Q000821:virology*
chemical_list: D019380:Anti-HIV Agents